Showing results (231-240 of 260) with videos related to

Sort By:
Pageof 26
Urologic Oncology|July 31, 2024
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safetyTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
Frontiers in Oncology|March 16, 2026
Penile involvement associated with renal pelvic squamous cell carcinoma: a case report and mechanistic considerationsKotaro Masaki, Takuya Tsujino, Hiroyuki Okada, et al.
Clinical and Translational Radiation Oncology|December 22, 2022
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survivalKeita Nakamori, Shogo Yamazaki, Kazumasa Komura, et al.
Elife|June 22, 2021
Restored TDCA and valine levels imitate the effects of bariatric surgeryMarkus Quante, Jasper Iske, Timm Heinbokel, et al.
Journal for Immunotherapy of Cancer|January 18, 2022
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancerKazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, et al.
BJU International|September 13, 2022
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinomaTaizo Uchimoto, Tatsuo Fukushima, Kazumasa Komura, et al.
International Journal of Clinical Oncology|December 10, 2024
Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitorsYasutaka Yamada, Kodai Sato, Shinichi Sakamoto, et al.
Prostate International|April 11, 2025
Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancerYasutaka Yamada, Shinichi Sakamoto, Takuya Tsujino, et al.
The Journal of Clinical Investigation|June 5, 2018
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5DKazumasa Komura, Yuki Yoshikawa, Teppei Shimamura, et al.
Molecular Cancer|November 19, 2023
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder CancerKazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, et al.
Pageof 26